People in the News

Jose Miguel Coego Rios is no longer the CFO of Centogene after his service agreement with the company expired Sept. 30. He is staying on as a consultant to the company until no later than Dec. 31, Centogene said in a regulatory filing.

David Shoultz has been appointed as the first chief business officer of Phase Genomics. He comes to the Seattle-based firm from Monod Bio, a spinout from the Institute for Protein Design that he cofounded and where he served as chief operating officer. Previously, he was a member of the global health product development team at the Bill & Melinda Gates Foundation, directed the global drug development program at PATH, and held scientific leadership positions at Neoleukin Therapeutics and PPD (now part of Thermo Fisher Scientific).

QuidelOrtho has appointed Jonathan Siegrist as executive VP of R&D and chief technology officer. He succeeds Werner Kroll, senior VP of R&D, who will support the transition until his retirement in March. Siegrist was most recently chief technology officer and head of assay R&D at Cepheid. Prior to that, he cofounded iGlyko, a diagnostics manufacturing company. He will spearhead QuidelOrtho’s R&D strategy, focusing on menu expansion and advancing critical platforms.

Inflammatix has appointed Sam Ajizian as chief medical officer, Jamie Lewis as chief commercial officer, and Laura Spencer Garth as general counsel. Ajizian previously served in multiple roles at Medtronic, including as chief medical officer for the firm's acute care and monitoring business. As Inflammatix prepares to launch its point-of-care TriVerity Test for the rapid assessment of infection type and severity, Ajizian will help to form a team of medical science liaisons to educate healthcare providers on the use of the test and the firm's Myrna real-time RT-LAMP instrument.

Lewis previously worked in leadership roles at Outset Medical and Intuitive Surgical. She also cofounded the Matter Solutions technology platform for virtual, mental, and behavioral healthcare services. She will build and manage Inflammatix's TriVerity commercial operations.

Garth previously worked as general counsel of Sereotaxis and Veran Medical Technologies. He also served as a litigator and trial attorney for Dolley Law and Bryan Cave Leighton Paisner. She will lead Inflammatix's legal and compliance functions.

CareDx has appointed Jing Huang to the newly created role of chief data and artificial intelligence officer. Huang previously served as senior VP of bioinformatics and data science at Veracyte and is currently president of the Bay Area Biotech-Pharma Statistical Workshop. She is the founding president of DahShu and chapter representative for the San Francisco Bay Area Chapter of the American Statistical Association. 

Alexander Johnson, former president of patient and testing services at CareDx, left the company effective Sept. 30. CareDx and Johnson entered into a consulting  agreement, under which Johnson will provide up to 40 hours of consulting services to the company per calendar month, for a period of six months, which may be subsequently extended upon written agreement. 

Akoya Biosciences has appointed Scott Mendel as chairman of its board. Mendel succeeds Robert Shepler, the company's founding chairman, who will remain on Akoya's board. Mendel previously served as president, CEO, and a board member of GenMark Diagnostics, a publicly traded molecular diagnostics company that was acquired by Roche in May 2020.

Oxford Nanopore Technologies has appointed Daniel Mahony as a non-executive director. A senior partner in growth investments at Novo Holdings, Mahony will serve as an Oxford Nanopore board member as it continues to address commercial opportunities in the biopharmaceutical industry. Mahony also currently chairs the UK BioIndustry Association and is a non-executive director of the Wellcome Sanger Institute.

Guy Harmelin, a non-executive director since 2020, has stepped down from the company this week to focus on various other directorship responsibilities.

Rob Wilson has been appointed as CEO of Manchester, UK-based enzyme engineering firm Imperagen, taking over from Andrew Almond, who is assuming the post of chief information officer. Previously, Wilson held leadership roles at Codexis and DNA Script.

Keith Loebner has been appointed to the board of directors of Integrated Biosciences, while Karl Sylvester, Uri Alon, and Wendy Young have been appointed as advisors. Loebner is a managing director at Sutter Hill Ventures, and an investor in the company. Sylvester is a professor of surgery and pediatrics at Stanford University; Alon is a professor at the Weizmann Institute of Science; and Young is an advisor to Google Ventures and a previous senior VP of Genentech's small molecule drug discovery division.